Corvus Q3 2026 update: Soquelitinib trials on track, $202.9M cash
Corvus Pharmaceuticals reported strong financial health with $202.9 million in cash and advanced its Phase 3 PTCL and Phase 2 atopic dermatitis programs for soquelitinib, indicating continued progress in its clinical pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed